Cancer Cases

Cancer incidence rate refers to the number of new cancers cases occurring in a specified population during a given year, expressed as the number of cancer cases per 100,000 population.1 

In 2018, the UK ranked 22nd amongst the 31 European countries studied for the incidence of pancreatic cancer, with 17 people in every 100,000 being diagnosed with the condition (ranging from 10 cases per 100,000 people in Cyprus to 24 per 100,000 people in Latvia).

The UK's incidence rate for this cancer type was lower than the European average of 20 cases per 100,000 people.

EU31

EU5

Cancer Deaths

Cancer mortality rate refers to the number of deaths caused by cancer occurring in a specified population during a given year, expressed as the number of cancer deaths per 100,000 population.2

In 2018, the UK ranked 26th amongst the 31 European countries studied for the mortality of pancreatic cancer, with 15 in every 100,000 people dying from the condition (ranging from 11 deaths per 100,000 people in Ireland to 23 per 100,000 people in Germany)

The UK's mortality rate for this cancer type was lower than the European average of 19 deaths per 100,000 people.

EU31
EU5

Downloads:

Note:

  • For this cancer type there is no information available on mortality at a country level for 1995

Reference for text:

2. National Cancer Institute. Cancer Mortality Rates.

References for graphs:

 


Cancer Survival

Survival refers to percentage of people that were diagnosed with cancer in a given year and who were still alive after a defined period of time (here defined as 5 years or more after being diagnosed).3

In Europe, there have been continuous increases in 5-year survival rates for the most common cancer types in all countries. However, the size of the increase differs between countries.

Between 2010 and 2014, the UK ranked 17th amongst the 28 European countries studied for the 5 year survival post cancer diagnosis, with 63% of people surviving 5 years or more after receiving a cancer diagnosis (ranging from 50% survival in Bulgaria to 68% in Cyprus).

EU31

EU5

Uptake of Cancer Medicines

Note: Data pertaining to the uptake of medicines was not available for pancreatic cancer medicines across all European countries examined by IHE, in 2018.

Last modified: 17 October 2021

Last reviewed: 5 November 2021